These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 10963315)
21. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Morishita R; Gibbons GH; Ellison KE; Nakajima M; Zhang L; Kaneda Y; Ogihara T; Dzau VJ Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8474-8. PubMed ID: 8104336 [TBL] [Abstract][Full Text] [Related]
22. Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. Fresta M; Chillemi R; Spampinato S; Sciuto S; Puglisi G J Pharm Sci; 1998 May; 87(5):616-25. PubMed ID: 9572914 [TBL] [Abstract][Full Text] [Related]
23. [Antisense nucleic acid therapy of influenza virus]. Hatta T; Abe T; Takai K; Takaku H Nihon Rinsho; 1997 Oct; 55(10):2765-71. PubMed ID: 9360404 [TBL] [Abstract][Full Text] [Related]
24. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Petch AK; Sohail M; Hughes MD; Benter I; Darling J; Southern EM; Akhtar S Biochem Pharmacol; 2003 Sep; 66(5):819-30. PubMed ID: 12948863 [TBL] [Abstract][Full Text] [Related]
25. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625 [TBL] [Abstract][Full Text] [Related]
26. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Stewart DA; Xu X; Thomas SD; Miller DM Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846 [TBL] [Abstract][Full Text] [Related]
27. Quantifying c-myc expression in c-myc antisense phosphorothioate oligodeoxynucleotide-treated leukemic and colon cancer cell lines. Li BD; Budnick RM; Russo CA; Anderson GR; Stewart CC J Surg Res; 1995 Oct; 59(4):485-92. PubMed ID: 7564322 [TBL] [Abstract][Full Text] [Related]
28. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Kimura S; Maekawa T; Hirakawa K; Murakami A; Abe T Cancer Res; 1995 Mar; 55(6):1379-84. PubMed ID: 7882339 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of c-myc expression in cells by targeting an RNA-protein interaction using antisense oligonucleotides. Coulis CM; Lee C; Nardone V; Prokipcak RD Mol Pharmacol; 2000 Mar; 57(3):485-94. PubMed ID: 10692488 [TBL] [Abstract][Full Text] [Related]
30. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Hughes JA; Aronsohn AI; Avrutskaya AV; Juliano RL Pharm Res; 1996 Mar; 13(3):404-10. PubMed ID: 8692733 [TBL] [Abstract][Full Text] [Related]
32. Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells. Tao M; Miyano-Kurosaki N; Takai K; Takaku H FEBS Lett; 1999 Jul; 454(3):312-6. PubMed ID: 10431829 [TBL] [Abstract][Full Text] [Related]
33. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Anfossi G; Gewirtz AM; Calabretta B Proc Natl Acad Sci U S A; 1989 May; 86(9):3379-83. PubMed ID: 2541445 [TBL] [Abstract][Full Text] [Related]
34. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. Bachmann AS; Surovoy A; Jung G; Moelling K J Mol Med (Berl); 1998 Feb; 76(2):126-32. PubMed ID: 9500678 [TBL] [Abstract][Full Text] [Related]
35. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525 [TBL] [Abstract][Full Text] [Related]
36. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Ginobbi P; Geiser TA; Ombres D; Citro G Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627 [TBL] [Abstract][Full Text] [Related]
37. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Algar EM; Khromykh T; Smith SI; Blackburn DM; Bryson GJ; Smith PJ Oncogene; 1996 Mar; 12(5):1005-14. PubMed ID: 8649791 [TBL] [Abstract][Full Text] [Related]
38. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406 [TBL] [Abstract][Full Text] [Related]
39. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation. Stewart DA; Thomas SD; Mayfield CA; Miller DM Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688 [TBL] [Abstract][Full Text] [Related]
40. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Hatta T; Takai K; Nakada S; Yokota T; Takaku H Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]